Convalescent plasma in Covid-19: Possible mechanisms of action
Open accessThe DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · cited 2×
“The virus was initially termed as 2019 novel coronavirus (2019-nCoV) [8], and it is currently known as SARS-CoV-2 producing the coronavirus disease 2019 (COVID-19).”
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Chan, J. F.-W., Yuan, S., Kok, K.-H., To, K. K.-W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C. C.-Y., Poon, R. W.-S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30154-9 · Cited by 8,944
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses
Su, S., Wong, G., Shi, W., Liu, J., Lai, A. C. K., Zhou, J., Liu, W., Bi, Y., & Gao, G. F. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.03.003 · Cited by 2,948
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
Zhang, Y., Xiao, M., Zhang, S., Xia, P., Cao, W., Jiang, W., Chen, H., Ding, X., Zhao, H., Zhang, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2007575 · Cited by 2,179 · cited 2×
“In this sense, a recent report in patients with COVID-19, showed that critically ill patients exhibited positivity for anti-cardiolipin IgA antibodies as well as for anti–β2-glycoprotein I IgA and IgG antibodies [66].”
ResultEffectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,960
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Phua, J., Weng, L., Ling, L., Egi, M., Lim, C.-M., Divatia, J. V., Shrestha, B. R., Arabi, Y. M., Ng, J., Gomersall, C. D., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30161-2 · Cited by 1,509
Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1729069 · Cited by 1,252
Coronavirus avian infectious bronchitis virus
Cavanagh, D. (2007) · Veterinary Research · doi:10.1051/vetres:2006055 · Cited by 1,053
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038 · cited 1×
“This combination was recently associated to worse outcomes when Hydroxychloroquine was administrated at high doses (QTc elongation and higher rates of lethality) [17].”
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K. D., Convalescent Plasma Study Group, Nguyen-Van-Tam, J. S., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 983
Use of convalescent plasma therapy in SARS patients in Hong Kong
Cheng, Y., Wong, R., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P., Wong, K. C., Leung, C. B., & Cheng, G. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 958
The convalescent sera option for containing COVID-19
Casadevall, A., & Pirofski, L.-A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 903
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 847
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754
Hung, I. F., To, K. K., Lee, C.-K., Lee, K.-L., Chan, K., Yan, W.-W., Liu, R., Watt, C.-L., Chan, W.-M., Lai, K.-Y., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq106 · Cited by 678
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
Gralinski, L. E., Sheahan, T. P., Morrison, T. E., Menachery, V. D., Jensen, K., Leist, S. R., Whitmore, A., Heise, M. T., & Baric, R. S. (2018) · mBio · doi:10.1128/mbio.01753-18 · Cited by 655
Molecular mimicry and autoimmunity
Rojas, M., Restrepo-Jiménez, P., Monsalve, D. M., Pacheco, Y., Acosta-Ampudia, Y., Ramírez-Santana, C., Leung, P. S. C., Ansari, A. A., Gershwin, M. E., & Anaya, J.-M. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.012 · Cited by 627
Self-citationWan, S., Yi, Q., Fan, S., Lv, J., Zhang, X., Guo, L., Lang, C., Xiao, Q., Xiao, K., Yi, Z., et al. (2020) · doi:10.1101/2020.02.10.20021832 · Cited by 562
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea
van Griensven, J., Edwards, T., de Lamballerie, X., Semple, M. G., Gallian, P., Baize, S., Horby, P. W., Raoul, H., Magassouba, N., Antierens, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511812 · Cited by 536
Anti-Inflammatory Actions of Intravenous Immunoglobulin
Nimmerjahn, F., & Ravetch, J. V. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090232 · Cited by 525
Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins
Wang, S.-F., Tseng, S.-P., Yen, C.-H., Yang, J.-Y., Tsao, C.-H., Shen, C.-W., Chen, K.-H., Liu, F.-T., Liu, W.-T., Chen, Y.-M. A., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.090 · Cited by 421
Zhang, B., Liu, S., Tan, T., Huang, W., Dong, Y., Chen, L., Chen, Q., Zhang, L., Zhong, Q., Zhang, X., et al. (2020) · Chest · doi:10.1016/j.chest.2020.03.039 · Cited by 420
Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China
Ye, M., Fu, D., Ren, Y., Wang, F., Wang, D., Zhang, F., Xia, X., & Lv, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25882 · Cited by 410
Soo, Y. O. Y., Cheng, Y., Wong, R., Hui, D. S., Lee, C. K., Tsang, K. K. S., Ng, M. H. L., Chan, P., Cheng, G., & Sung, J. J. Y. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00956.x · Cited by 381
Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review
Rajendran, K., Krishnasamy, N., Rangarajan, J., Rathinam, J., Natarajan, M., & Ramachandran, A. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25961 · Cited by 360
Ahn, J. Y., Sohn, Y., Lee, S. H., Cho, Y., Hyun, J. H., Baek, Y. J., Jeong, S. J., Kim, J. H., Ku, N. S., Yeom, J.-S., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e149 · Cited by 352
Ko, J.-H., Seok, H., Cho, S. Y., Ha, Y. E., Baek, J. Y., Kim, S. H., Kim, Y.-J., Park, J. K., Chung, C. R., Kang, E.-S., et al. (2018) · Antiviral Therapy · doi:10.3851/imp3243 · Cited by 323
Convalescent plasma: new evidence for an old therapeutic tool?
Marano, G., Vaglio, S., Pupella, S., Facco, G., Catalano, L., Liumbruno, G. M., & Grazzini, G. (2016) · PubMed · doi:10.2450/2015.0131-15 · Cited by 322
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin
Bayry, J., Lacroix-Desmazes, S., Carbonneil, C., Misra, N., Donkova, V., Pashov, A., Chevailler, A., Mouthon, L., Weill, B., Bruneval, P., et al. (2003) · Blood · doi:10.1182/blood-2002-05-1447 · Cited by 306
Intravenous immunoglobulin in neurology—mode of action and clinical efficacy
Lünemann, J. D., Nimmerjahn, F., & Dalakas, M. C. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.253 · Cited by 301
Hyperimmune IV Immunoglobulin Treatment
Hung, I. F. N., To, K. K. W., Lee, C.-K., Lee, K.-L., Yan, W.-W., Chan, K., Chan, W.-M., Ngai, C.-W., Law, K.-I., Chow, F.-L., et al. (2013) · Chest · doi:10.1378/chest.12-2907 · Cited by 286
Prasad, N. K. A., Papoff, G., Zeuner, A., Bonnin, E., Kazatchkine, M. D., Ruberti, G., & Kaveri, S. V. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3781 · Cited by 279
Safety of intravenous immunoglobulin (IVIG) therapy
Katz, U., Achiron, A., Sherer, Y., & Shoenfeld, Y. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2006.08.011 · Cited by 265
Self-citationHsueh, P.-R., Huang, L.-M., Chen, P.-J., Kao, C.-L., & Yang, P.-C. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.01009.x · Cited by 261
Yeh, K.-M., Chiueh, T.-S., Siu, L. K., Lin, J.-C., Chan, P. K. S., Peng, M.-Y., Wan, H.-L., Chen, J.-H., Hu, B.-S., Perng, C.-L., et al. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki346 · Cited by 247
Tackenberg, B., Jelčić, I., Baerenwaldt, A., Oertel, W. H., Sommer, N., Nimmerjahn, F., & Lünemann, J. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807319106 · Cited by 242
Shoenfeld, Y. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102538 · Cited by 227
Self-citationRokni, M., Ghasemi, V., & Tavakoli, Z. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2107 · Cited by 219
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
Kiessling, P., Lledo-Garcia, R., Watanabe, S., Langdon, G., Tran, D., Bari, M., Christodoulou, L., Jones, E., Price, G., Smith, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan1208 · Cited by 211
Original antigenic sin: A comprehensive review
Vatti, A., Monsalve, D. M., Pacheco, Y., Chang, C., Anaya, J.-M., & Gershwin, M. E. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.04.008 · Cited by 207
Self-citationThe MHC class I–like Fc receptor promotes humorally mediated autoimmune disease
Akilesh, S., Petkova, S., Sproule, T. J., Shaffer, D. J., Christianson, G. J., & Roopenian, D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18838 · Cited by 196
Treatment of West Nile Virus Encephalitis with Intravenous Immunoglobulin
Shimoni, Z., Niven, M. J., Pitlick, S., & Bulvik, S. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0704.010432 · Cited by 181
Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how?
Tiberghien, P., de Lamballerie, X. N., Morel, P., Gallian, P., Lacombe, K., & Yazdanpanah, Y. (2020) · Vox Sanguinis · doi:10.1111/vox.12926 · Cited by 168
Hansen, R., & Balthasar, J. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613331 · Cited by 164
Abe, Y., Horiuchi, A., Miyake, M., & Kimura, S. (1994) · Immunological Reviews · doi:10.1111/j.1600-065x.1994.tb00854.x · Cited by 161
Maddur, M. S., Vani, J., Hegde, P., Lacroix‐Desmazes, S., Kaveri, S. V., & Bayry, J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.1102 · Cited by 156
IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes
Séïté, J.-F., Cornec, D., Renaudineau, Y., Youinou, P., Mageed, R. A., & Hillion, S. (2010) · Blood · doi:10.1182/blood-2009-12-261461 · Cited by 154
Yu, H., Gao, Z., Feng, Z., Shu, Y., Xiang, N., Zhou, L., Yang, H., Feng, S., Peng, Z., Li, Z., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002985 · Cited by 148
On the molecular determinants of the SARS-CoV-2 attack
Kanduc, D., & Shoenfeld, Y. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108426 · Cited by 144
Self-citationTreatment of severe acute respiratory syndrome with convalescent plasma.
Wong, V. W., Dai, D., Wu, A. K. L., & Sung, J. J. �. (2003) · PubMed · Cited by 142
Gorse, G. J., Donovan, M. M., & Patel, G. B. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25715 · Cited by 134
Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow
Garraud, O., Heshmati, F., Pozzetto, B., Lefrère, F., Girot, R., Saillol, A., & Laperche, S. (2016) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2015.12.003 · Cited by 130
The Role for Intravenous Immunoglobulin in the Treatment of West Nile Virus Encephalitis
Haley, M., Retter, A. S., Fowler, D. H., Gea‐Banacloche, J., & O’Grady, N. P. (2003) · Clinical Infectious Diseases · doi:10.1086/377172 · Cited by 128
Hansen, R. J., & Balthasar, J. P. (2002) · Blood · doi:10.1182/blood.v100.6.2087 · Cited by 126
Ebola virus disease: An emerging and re-emerging viral threat
Rojas, M., Monsalve, D. M., Pacheco, Y., Acosta‐Ampudia, Y., Ramírez-Santana, C., Ansari, A. A., Gershwin, M. E., & Anaya, J. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102375 · Cited by 126
Self-citationPathogenicity of Turkey Coronavirus in Turkeys and Chickens
Ismail, M. M., Tang, Y., & Saif, Y. Μ. (2003) · Avian Diseases · doi:10.1637/5917 · Cited by 113
Mechanisms of action of intravenous immunoglobulin
Chaigne, B., & Mouthon, L. (2016) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2016.12.017 · Cited by 110
The management of coronavirus infections with particular reference to SARS
Wong, S. S. Y., & Yuen, K. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn243 · Cited by 102
Antibody-Dependent Enhancement of Viral Infections
Kulkarni, R. (2020) · Springer eBooks · doi:10.1007/978-981-15-1045-8_2 · Cited by 91
West Nile Virus Neutralization by US Plasma–Derived Immunoglobulin Products
Planitzer, C. B., Modrof, J., & Kreil, T. R. (2007) · The Journal of Infectious Diseases · doi:10.1086/519392 · Cited by 90
Shrestha, S., Wiener, H. W., Shendre, A., Kaslow, R. A., Wu, J., Olson, A. K., Bowles, N. E., Patel, H., Edberg, J. C., & Portman, M. A. (2012) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.962464 · Cited by 85
Ebola virus convalescent blood products: Where we are now and where we may need to go
Burnouf, T., & Seghatchian, J. (2014) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2014.10.003 · Cited by 76
Successful treatment of avian influenza with convalescent plasma.
Kong, L.-B., & Zhou, B. P. (2006) · PubMed · Cited by 73
BAFF, a New Target for Intravenous Immunoglobulin in Autoimmunity and Cancer
Pottier, L. L., Bendaoud, B., Dueymes, M., Daridon, C., Youinou, P., Shoenfeld, Y., & Pers, J. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9082-2 · Cited by 72
Self-citationComparison of different IVIg preparations on IL-17 production by human Th17 cells
Maddur, M. S., Kaveri, S. V., & Bayry, J. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.02.007 · Cited by 65
Tjon, A. S. W., van Gent, R., Jaadar, H., van Hagen, P. M., Mancham, S., van der Laan, L. J. W., Boekhorst, P. A. W. T., Metselaar, H. J., & Kwekkeboom, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301260 · Cited by 63
Meregalli, C., Marjanovic, I., Scali, C., Monza, L., Spinoni, N., Galliani, C., Brivio, R., Chiorazzi, A., Ballarini, E., Rodriguez‐Menendez, V., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1270-x · Cited by 60
Kozicky, L. K., Zhao, Z., Menzies, S. C., Fidanza, M., Reid, G. S. D., Wilhelmsen, K., Hellman, J., Hotte, N., Madsen, K. L., & Sly, L. M. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3vma0315-078r · Cited by 58
Kim, D. J., Lee, S. K., Kim, J. Y., Na, B.-J., Hur, S. E., Lee, M., & Kwak-Kim, J. Y.-H. (2014) · American Journal of Reproductive Immunology · doi:10.1111/aji.12208 · Cited by 56
Othy, S., Topçu, S., Saha, C., Kothapalli, P., Lacroix‐Desmazes, S., Käsermann, F., Miescher, S., Bayry, J., & Kaveri, S. V. (2014) · European Journal of Immunology · doi:10.1002/eji.201444440 · Cited by 55
Séïté, J.-F., Guerrier, T., Cornec, D., Jamin, C., Youinou, P., & Hillion, S. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.05.014 · Cited by 48
Sharma, M., Schoindre, Y., Hegde, P., Saha, C., Maddur, M. S., Victor, E. S., Gilardin, L., Lecerf, M., Bruneval, P., Mouthon, L., et al. (2014) · Scientific Reports · doi:10.1038/srep05672 · Cited by 43
Advances in clinical diagnosis and treatment of severe acute respiratory syndrome
Nie, Q. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i6.1139 · Cited by 38
Intravenous immunoglobulin up‐regulates the expression of the inhibitory FcγIIB receptor on B cells
Nikolova‐Ganeva, K., Tchorbanov, A. I., Djoumerska‐Alexieva, I., Nikolova, M. H., & Vassilev, T. L. (2009) · Immunology and Cell Biology · doi:10.1038/icb.2009.36 · Cited by 36
Klehmet, J., Göhler, J., Ulm, L., Köhler, S., Meisel, C., Meisel, A., & Harms, H. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307708 · Cited by 33
Issekutz, A. C., Rowter, D., Miescher, S., & Käsermann, F. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.05.003 · Cited by 22
Mechanisms of immunotherapy: a historical perspective
Shakir, E. M., Cheung, D. S., & Grayson, M. H. (2010) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2010.09.012 · Cited by 21
Immunotherapy in Clinical Medicine: Historical Perspective and Current Status
Shahani, L., Singh, S., & Khardori, N. M. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.04.001 · Cited by 19
Therapeutic normal IgG intravenous immunoglobulin activates Wnt-β-catenin pathway in dendritic cells
Karnam, A., Rambabu, N., Das, M., Bou-Jaoudeh, M., Delignat, S., Käsermann, F., Lacroix‐Desmazes, S., Kaveri, S. V., & Bayry, J. (2020) · Communications Biology · doi:10.1038/s42003-020-0825-4 · Cited by 18
Jin, J., Gong, J., Lin, B., Li, Y., & He, Q. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.03.006 · Cited by 6
Cited by
Agarwal, A., Mukherjee, A., Kumar, G., Chatterjee, P., Bhatnagar, T., & Malhotra, P. (2020) · BMJ · doi:10.1136/bmj.m3939 · Cited by 718
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Liu, S. T. H., Lin, H.-M., Baine, I., Wajnberg, A., Gumprecht, J. P., Rahman, F., Rodriguez, D., Tandon, P., Bassily-Marcus, A., Bander, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1088-9 · Cited by 493
Immune response in COVID-19: A review
Chowdhury, M. A., Hossain, N., Kashem, M. A., Shahid, M. A., & Alam, A. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.07.001 · Cited by 445
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
“This classical adaptive prevention approach has been applied to many infectious diseases including SARS-CoV, MERS-CoV, and the H1N1 infections [184].”
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19
Rodríguez, Y., Novelli, L., Rojas, M., De Santis, M., Acosta-Ampudia, Y., Monsalve, D. M., Ramírez-Santana, C., Costanzo, A., Ridgway, W. M., Ansari, A. A., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102506 · Cited by 312
Self-citation
Metadata
- Authors
- Rojas, M., Rodríguez, Y., Monsalve, D. M., Acosta-Ampudia, Y., Camacho, B., Gallo, J. E., Rojas-Villarraga, A., Ramírez-Santana, C., Díaz-Coronado, J. C., Manrique, R., Mantilla, R. D., Shoenfeld, Y., & Anaya, J.-M.
- Venue
- Autoimmunity Reviews
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 19
- Issue
- 7
- Pages
- 102554
- ISSN
- 1568-9972 (ISSN-L)
- OpenAlex
- W3021816206
- Cited by
- 491
- References
- 91
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.